CLEVELAND, Feb. 21, 2018 -- Lincoln Electric Holdings, Inc., (Nasdaq:LECO) announced today that its Board of Directors has declared a quarterly cash dividend of $0.39 per common share, payable April 13, 2018 to shareholders of record as of March 29, 2018.
Business
Lincoln Electric is the world leader in the design, development and manufacture of arc welding products, robotic arc welding systems, plasma and oxyfuel cutting equipment and has a leading global position in the brazing and soldering alloys market. Headquartered in Cleveland, Ohio, Lincoln has 63 manufacturing locations, including operations and joint ventures in 23 countries and a worldwide network of distributors and sales offices covering more than 160 countries. For more information about Lincoln Electric and its products and services, visit the Company's website at www.lincolnelectric.com.
Contact
Amanda Butler
Vice President, Investor Relations & Communications
Tel: 216.383.2534
Email: [email protected]


Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
OpenAI Restricts Astra AI Over Cyberattack Risks
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
DeepSeek to Raise AI API Prices as Demand for New Models Surges
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings
Nintendo Shares Jump as Switch 2 Sales Boost Earnings
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 



